BEXIMCO PHARMACEUTICALS LTD.
News Release
July 2011
Beximco Pharma introduces Ribox-120
Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced new strength of etoricoxib, Ribox-120, for the management of pain associated with ankylosing spondylitis, acute gouty arthritis & dental procedure.
Ribox-120 is preparation of Etoricoxib 120mg. Etoricoxib is a COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1). Ribox-120 is indicated for the symptomatic relief of ankylosing spondylitis, the pain and signs of inflammation associated with acute gouty arthritis and dental pain. As etoricoxib is a selective COX-2 inhibitor so it only act on pain & inflammation without interfering COX-1 mediated gastro protective functions. As a result, Ribox reduce pain & inflammation with better GI safety. Besides this Beximco Pharma already launched Ribox-60 & Ribox-90.
END
Welcome to the registered Health Professionals, to this exclusive Doctors only area. This provides you access to latest medical updates, events, guidelines and information relevant to your practice. If you are not a registered doctor please do not enter this area. 
Life's all about staying healthy and enjoying the good things in life! However, illness is inevitable at all stages of life. In this area learn about the common health problems and how to deal with your and your family's illness.